UTMD
UTAH MEDICAL PRODUCTS INCMarquee-fund ownership over time
This quarter's activity
New positions opened
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $64 | $64 | -1% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $64 | $64 | +0% |
| AQR Capital Management re-entered | Q3 2024(8Q snapshot) | 7Q | $64 | $64 | +0% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $64 | $64 | +0% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 2× in & out | Q1 2026 | Q2 2026 | → $63 | -3% |
| Two Sigma Investments | Q3 2024 | Q2 2026 | → $63 | -1% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at UTAH MEDICAL PRODUCTS INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 29, 2026 — the most recent Form 4 on file — not from today.
- Form 40001733614-26-000001May 29, 2026
- Form 40001733614-25-000004Nov 25, 2025
- Form 40001733614-25-000002Sep 5, 2025
- Form 40001733614-25-000001Aug 26, 2025
- Form 40001733614-24-000003Nov 8, 2024
- Form 40001733614-24-000002Jul 22, 2024
- Form 40001733614-24-000001May 17, 2024
- Form 40001733614-23-000005Dec 26, 2023
- Form 40001733614-23-000004Jun 20, 2023
- Form 40001733614-23-000003May 19, 2023
- Form 40001733614-23-000002Mar 17, 2023
- Form 40001733614-23-000001Feb 9, 2023
- Form 40001733614-22-000009Dec 6, 2022
- Form 40001733614-22-000008Nov 21, 2022
- Form 40001733614-22-000007Nov 17, 2022
Fundamentals
XBRL · UTAH MEDICAL PRODUCTS INCAnnual figures sourced directly from UTAH MEDICAL PRODUCTS INC's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for UTAH MEDICAL PRODUCTS INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QUTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILINGMay 12, 2026
- 8-KUTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILINGMay 4, 2026
- 8-KUTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILINGApr 23, 2026
- DEF 14APROXY STATEMENTApr 2, 2026
- 10-KUTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILINGMar 27, 2026
- 8-KUTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILINGJan 29, 2026
- 10-QUTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILINGNov 14, 2025
- 8-KUTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILINGNov 4, 2025
- 8-KUTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILINGOct 23, 2025
- 10-QUTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILINGAug 12, 2025
- 8-KUTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILINGJul 24, 2025
- 10-QUTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILINGMay 15, 2025
- 8-KUTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILINGMay 5, 2025
- 8-KUTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILINGApr 29, 2025
- DEF 14AUTAH MEDICAL PRODUCTS, INC. - DEF 14AApr 4, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q1 2026 | Q2 2026 | $65 | $63 | -3% |
| AQR Capital Management | Q3 2025 | open | $56 | $64 | +14% |
| Citadel Advisors | Q3 2024 | Q4 2025 | $64 | $55 | -14% |
| Two Sigma Investments | Q3 2024 | Q2 2026 | $64 | $63 | -1% |
| D.E. Shaw | Q3 2024 | open | $64 | $64 | +0% |
| AQR Capital Management | Q3 2024 | Q1 2025 | $64 | $59 | -7% |
| Millennium Management | Q3 2024 | open | $64 | $64 | +0% |
| Renaissance Technologies | Q3 2024 | open | $64 | $64 | -1% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.